CDK7 and neoplasm: As clinical trials progress, analyses of tumour features enriched in subsets of patients that are intrinsically resistant to CDK7 inhibitors, or those who acquire resistance after initially responding well, should help shed light on mechanisms of CDK7 inhibitor resistance.